top of page

News & Events

11. January 2022

Cellin Technologies and Hospital of Reconstructive Surgery collaboration project got  1 155 500 EUR funding from Enterprise Estonia (EAS). The project is funded as part of the European Union’s response to the COVID-19 pandemic

Project title:

"Use of activated autologous mesenchymal stem cells in the treatment of peripheral vascular diseases"

Aim of the project and results:

The aim of the joint action of the Hospital Of Reconstructive Surgery (HRS) and Cellin Technologies (CT) is to treat patients with critical limb ischemia with a novel cellular drug in a frame of hospital exemption. Drug manufacturing technology involves isolating regenerative cells from a patient's adipose tissue, culturing and treating the cells in a laboratory, and returning them to the same patient. We have started the process of patenting the relevant technology.

The use of this drug is intended for people for whom it is not possible to find a solution by conventional methods and whose symptoms are so severe that the only option is leg amputation. It is necessary to pay attention here to the fact that after amputation of the leg, a large part of patients has lost their ability to move independently. Patients who have their legs amputated above the knee can regain their independent mobility in only 30% of cases. The developed technology is expected to reduce ischemic pain (reduce inflammation in the leg), promote the formation of new blood vessels and save up to 30% of the legs that are amputated today. In the long perspective, this treatment method is cost-effective from the point of view of the Health Insurance.

The safety and efficacy of the treatment shall be assessed during the hospital exemption. The positive outcome of this activity will allow us to advance to Phase I / II of clinical trials with our novel stem cell-based drug. The impact of this project on the goal is directly positive, it is a direct help to carry out one of the crucial steps in achieving the final goal of the companies. The impact of the project on Estonian healthcare system would be undoubtedly great. It would be noticed in the world and would benefit Estonia as a country with a great reputation for biotechnology in the world.

Summary of the project for the public:

The aim of this project is to develop a novel cellular drug for the treatment of ischemic blood vessels. The developed drug is a “piece of art” technology because it is made from the patient's stem cells for each specific case. This technology is based on a patent application filed by us (HRS and CT) which is in the international phase and which has been positively evaluated by experts. This treatment technology can save up to 30% of the legs that are amputated today due to ischemia.


October 18, 2016

Greg McGarrell (UK) holds a seminar:

Status of biotherapeutics in canine and equine medicine  - When, where and what to use?

Seminar will be held in Tallinn on October 31, 2016.

Nupsala Veterinary Services

September 5, 2016

A seminar about Regenerative Medicine in Veterinary will be held in cooperation with Cellin Technologies

Seminars will be held in Tartu on September 28 and in Tallinn on October 3, 2016.

Please contact us for more information.

regenerative medicine in veterinary

June 8-9, 2016

Cellin Technologies was one of the organizers at the International Conference on Cell Therapy and Tissue Engineering: Regenerative Medicine - New Developments

The Conference in Tallinn, Estonia was a successful attempt to bring four parties - researchers, regulators, clinicians and back-up forces together.

conference on cell therapy

November 25, 2015

Cellin Technologies participated in CPhI Madrid 2015

We attended the world's leading pharmaceutical event. 

CPhI Madrid

August 27-28, 2015

Cellin Technologies was one of the organizers at the International Conference on Cell Therapy and Tissue Engineering: Regenerative Medicine - Challenges and Controversies

In Tallinn, Estonia we heard presentations about regenerative medicine`s challenges and controversies. Such names like Keith March (USA), Paula Salmikangas (FIN), Johannes Boltze (GER), Anne Nossent (NED), Toomas Neuman (EST), Andrus Loog (EST) and Toivo Maimets (EST) are few of the experts who stepped up with their presentations in the conference.

conference on cell therapy

April 15, 2015

Producing Colorectal Cancer Vaccine: Combining Forces between Denmark and Estonia

International Pharmaceutical Industry, Volume 7, Issue 1

An article about the vaccine MelCancerVac and the collaboration between Denmark and Estonia. The article is on pages 41-45.

colorectal cancer vaccine

March 19, 2015

Cellin Technologies - cell therapy products

Biotech 365

An article about the company and the production of melanoma cell lysate.

cell therapy products

January 21, 2015

Estonian company begins production of treatment to cure colorectal cancer

International Pharmaceutical Industry

Cellin Technologies LLC ‒ a GMP cell therapy products manufacturing company located in Tallinn, Estonia ‒ this week started production of melanoma cell lysate, the critical raw material required for the manufacture of MelCancerVac, the colorectal cancer vaccine developed by DanDrit Biotech.

treatment to cure colorectal cancer

February 12, 2014

Developing a New Branch of Medicine Cell Therapy in Estonia

Journal for Clinical Studies

A recent announcement from Estonia discussed the launching of the first human stem cell production laboratory in the Baltic States. Behind the lab is a wider initiative, the Estonian Cell Therapy Cluster, with the objective of developing the field of cell therapy.

stem cell production laboratory

September 27-28, 2013

Cellin Technologies participated in Symposium in Pärnu:

Cell therapy medicine - a breakthrough in regenerative medicine

In cooperation with the Cell Therapy Cluster, a symposium was held in Pärnu, Estonia. The symposium brought together experts to discuss developments in cell therapy and medicine.

cell therapy

August 15, 2013

Opening of the GMP cleanroom in Tallinn, Estonia

Together with Biolaborid LLC, Cellin Technologies launches a state-of-the-art GMP cleanroom facility for the production of cell therapy medicinal products of the highest quality.

gmp cleanroom opening

August 15, 2013

This article is only in estonian.

Tallinnas avatud labor tahab tuua kasu kogu Euroopa meditsiinile

ERR, "Aktuaalne kaamera"

Uus labor on täiesti puhas ruum, kuhu pääseb vaid paar töötajat. Labor kasvatab rakke, mida saab kasutada ravimina, vahendas "Aktuaalne kaamera". 

gmp cleanroom

August 13, 2013

Stem Cell Research Lab to Open at Tehnopol

News from Estonian Public Broadcasting

In cooperation with the Cell Therapy Cluster, the Enterprise Estonia and EU-funded lab will be used to develop high-quality cell treatment products.

stem cell research lab

March 28, 2013

Cellin Technologies participated in conference in Tallinn: Stem Cells in a Clinic and in a Laboratory


We heard presentations from Mr Andrus Loog (MD, FESVS, Consultant Vascular Surgeon), Mr Olavi Vasar (MD, FESPS, Consultant Plastic and Vascular Surgeon), Mr Toomas Neuman (PhD, Cell Biologist) and Mr (Jüri Laasik, MD, Chief Medical Manager).

stem cells conference
bottom of page